To identify the role and to explore the mechanism of extracellular 5 0 -nucleotidase (CD73) in human breast cancer growth, CD73 expression was measured firstly in breast cancer tissues and cell lines, and then interfered with or over-expressed by recombinant lentivirus in cell lines. Impacts of CD73 on breast cancer cell proliferation and cell cycle were investigated with colony formation assay, CCK-8 and flow cytometry. The relationship between CD73 and AKT/GSK-3b/b-catenin pathway was assessed with adenosine, adenosine 2A receptor antagonist (SCH-58261), adenosine 2A receptor agonist (NECA), CD73 enzyme inhibitor (APCP) and Akt inhibitor (MK-2206). Moreover, the effect of CD73 on breast cancer growth in vivo was examined with human breast cancer transplanting model of nude mice. The results showed that the expression of CD73 was high in breast cancer tissues and increased with advanced tumor grades and lympho-node status. CD73 expression was higher in more malignant cells, and CD73 overexpression promoted breast cancer cell proliferation in both in vivo and in vitro. It activated AKT/GSK-3b/b-catenin/cyclinD1 signaling pathway through CD73 enzyme activity and other mechanism.
Breast cancer is a leading cancerous death in women around the world. Its incidence rate has been rising with a trend toward young age. 1 Ecto-5 0 -nucleotidase (CD73), a 70 kDa glycosylated protein bounding to the outer surface of the plasma membrane by a glycosyl phosphatidyl inositol (GPI) anchor, is over-expressed in a variety of tumors, including breast cancer. [2] [3] [4] [5] Major function of CD73 is catalyzing extracellular 5 0 -AMP to adenosine that plays important roles in many physiological and pathophysiological circumstances through adenosine receptor (A1, A2A, A2B and A3 AR). 6 Up-regulation of CD73 is associated with highly invasive cancer phenotype, drug resistance and tumor-promoting functions. 7 We found that CD73 could promote growth and metastasis of human breast cancer cells, while our knowledge on the mechanisms remains limited, which may or may not depend on the enzyme activity. Wnt/b-catenin and PI3K/Akt, two crucial signal pathways in cell growth and development, also play important roles in tumorigenesis. [8] [9] [10] There is a "crosstalk" between the two pathways. In Wnt/b-catenin signaling pathway, glycogen synthesis kinase-3b (GSK-3b) can phosphorylate b-catenin, causing degradation of b-catenin, which can be inhibited by AKT-induced-phosphorylation of GSK-3b. As a result, b-catenin accumulates in cells and moves into nuclear, leading to the activated transcription of downstream target genes, such as cyclinD1 11 and c-myc, to promote cell growth. CD73 was reported to activate PI3K/Akt signaling pathways in cardiovascular, dental pulp stem, glioma and prostate cancer cells. [12] [13] [14] We also found that CD73 promote breast cancer growth via cyclinD1 in previous studies. 15 Thus, CD73 could be used as a valuable diagnostic and prognostic indicator in breast carcinoma. [16] [17] [18] In this study, we investigated the relationship of CD73 and AKT/GSK-3b/b-catenin signaling pathway in human breast cancer growth using in vivo and in vitro experiments.
Material and Methods

Tumor tissues
Breast cancer tissues were obtained from Department of Pathology, Huashan Hospital, Fudan University. The study was approved by the institutional review board, Fudan University. One hundred nineteen consecutive invasive breast cancer cases who accepted modified radical mastectomy in 2003 were included in this study. All patients were not subjected to chemotherapy and radiotherapy before surgery. Hematoxylin and eosin (H&E) slides were reviewed by two pathologists. Histological grade and clinical stage were determined according to the WHO classification of breast tumor released in 2012.
What's new?
The enzyme CD73 has been associated with tumor growth in many types of cancer, but investigations into its utility as a prognostic factor have produced mixed results. Here, the authors found high CD73 levels in breast cancer cells, and even higher in tumors with advanced stage. They found that boosting CD73 expression promoted cancer growth both in cell culture and in mouse models. Next, they showed that CD73 activated the AKT/GSK3beta/beta-catenin signaling pathway, which spurs tumor growth. Therefore, the presence of CD73 could be an important prognostic tool for breast cancer. 
Immunohistochemistry
The immunohistochemistry study was performed with Leica BOND-MAX TM fully automated system according to the manufacture's protocol (Leica Microsystems GmbH, Wetzlar, Germany). Briefly, 4-lm-thick sections were de-paraffinized and pre-treated with the Epitope Retrieval Solution 2 (EDTA-buffer pH8.8) at 988C for 20 min. After washing steps, peroxidase blocking was carried out for 10 min using the Bond Polymer Refine Detection Kit DC9800 (Leica Microsystems GmbH). Tissues were again washed, incubated with the CD73 (Cat#: AP2014b; dilution, 1:25; ABGENT, San Diego, CA) for 60 min, and then incubated with polymer for 10 min and developed with 3,3-diaminobenzidine for 10 min.
Cells culture
All cell lines were obtained from American Type Culture Collection (ATCC), and cultured at 378C, 5% CO 2 , saturated humidity conditions. MCF10A was cultured in Dulbecco's modified Eagle's medium (DMEM)/F12 with 5% horse serum (Gibco, USA), 0.5 g/mL hydrocortisone, 100 ng/mL cholera toxin, 10 g/ mL human insulin (Sigma, USA) and 20 ng/mL of EGF (PeproTech, USA). Other cells were cultured in high glucose DMEM (Gibco, USA) with 10% fetal bovine serum (Gibco, USA).
Recombinant lentivirus
CD73 interference and overexpressing recombinant lentivirus were constructed, packaged, amplified and titrated with a "three plasmids system (Genechem, China)." SiRNAinterference sequences and overexpressing sequences of CD73 were designed according to its gene sequence (Gene ID: 4907). SiRNA sequences targeted at "TCTCAATCAT GCCGCTTTA" and "CATTGATGAACGCAACAAT" were proved to be effective. According to preliminary results, adherent monolayer breast cancer cells were infected with recombinant lentivirus at multiplicities of infection 30 and 50, respectively. Medium was refreshed in 12 hr after infection. The effects were examined by real time PCR and Western blot one week later.
Colony formation assay
For the colony formation assay, 1 3 10 3 cells were plated in 60 mm culture dishes, and replenished every 2-3 days with complete medium. After 14 days incubation, the cells were fixed with methanol and stained with 0.5% crystal violet. Visible colonies were manually counted. All experiments were performed in triplicate. The clone formation rate (CFR) was computed according the following formula: CFR 5 clone counts/seeded cell counts 3 100%.
Cell counting kit-8 assay 
Cell cycle analysis by flow cytometry
Cell cycle was analyzed by ethanol-fixed cells stained with propidium iodide in buffer containing RNase A. The DNA content was assessed with a FACS Calibur Flow Cytometer (Becton-Dickinson, San Jose, CA). The proliferation index (PIa)
Murine xenograft model for tumorigenicity
The effect of CD73 on tumorigenicity was assessed by subcutaneous injection of 2 3 10 6 MB-MDA-231 cells infected with CD73 siRNA lentivirus or control lentivirus into each 4-week BALB/C athymic nude mouse. Five mice were in each CD73 siRNA and control group. Tumors were measured every 3 days by a vernier caliper, and the mean volume of a tumor was calculated according to the formula: a 3 b 2 3 0.5 (a, largest diameter; b, perpendicular diameter). Tumors were excised and weighed 20 days later. 
Real-time PCR and Western blot
Total RNA and proteins were isolated routinely. Then, mRNA and protein expressions were determined by real-time PCR and Western blot assays as previously described. The primer sequences of the housekeeping gene b-actin and aim genes are as below: b-actin forward primer: GGTGGCTTTT AGGATGGCAAG, b-actin reverse primer: ACTGGAACGGT GAAGGTG ACAG; CD73 forward primer: ATTGCAAAGT GGTTCAAAGTCA, CD73 reverse primer: ACACTTGGCC AGTAAAATAGGG; Primary antibodies against b-actin (KangWei Century, China), CD73, AKT, P-AKT, GSK-3b, P-GSK-3b-, b-catenin (Santa Cruz, CA) were incubated with 
Statistical analysis
Data were averaged from three or more separate experiments, calculated and presented as the mean 6 SD. The t test and one-way ANOVA were used to detect differences between two groups and among multiple groups, respectively. p < 0.05 was considered as statistically significant. All analysis was performed with SPSS 11.5 software.
Results
CD73 expression in breast cancer tissues and cell lines
CD73 positive stain was observed on the cytomembrane and in the cytoplasm of breast cancer tissues (Fig. 1a) , especially on the cytomembrane [ Fig. 1a(c) ]. The stain became stronger with increased tumor grade and lympho-node metastasis (Table 1) , and was rather weaker in the residential normal tissues. CD73 expression could be detected in breast cancer tissues and cell lines MDA-MB-231, BT-549, MCF-7, T-47 D by RT-PCR and Western blot (Fig. 1b) . CD73 expression was higher in more malignant cells (MDA-MB-231 and BT-549) than less malignant cells (MCF-7 and T-47 D).
The effects of recombinant CD73 interference and overexpressing lentivirus
Four kinds of recombinant CD73 interference lentivirus were constructed and infected into human breast cancer cells MDA-MB-231 and BT-549 that had a high background expression of CD73. Recombinant lentivirus V1 and V3 were validated to substantially suppress CD73 expression at both mRNA and protein levels [ Fig. 1c(a and b) ]. On the other hand, recombinant overexpressing lentivirus increased CD73 expression at both mRNA and protein levels in MCF-7 and T-47 D cells that had a low background CD73 expression [ Fig. 1c(c and d) ].
CD73 promoted breast cancer cells growth and cell cycles in vitro
Assessed by colony formation assay and CCK-8 assay, colony formation ability and viability increased after CD73 overexpression by lentivirus infection in MCF-7 cells, while decreased after CD73 suppression by siRNA lentivirus infection in MDA-MB-231 cells (Figs. 2a and 2b) . Furthermore, more S and less G0/G1 phase were detected with flow cytometry after CD73 overexpression, which increases PIa. Conversely, more G0/G1 and less S phase were found after CD73 suppression, which decreases PIa (Fig. 2c) .
CD73 promoted cyclinD1 expression through increasing b-catenin nuclear transfer
We previously found that CD73 promoted cyclinD1, an important cell cycle protein, in breast cancer cells. Since bcatenin is one of the most important molecules to regulate cyclinD1 transcription, whose activated form was b-catenin in the nuclear (N-b-catenin), we examined expressions of Nb-catenin and cyclinD1 and found that they increased after CD73 overexpression (Fig. 3a) and decreased after CD73 suppression (Fig. 3b) .
CD73 stimulated AKT/GSK-3b/b-catenin signal pathway
In this study, we found that phosphorylated AKT and phosphorylated GSK-3b increased after CD73 overexpression in MCF-7 cells, and decreased after CD73 suppression in MDA-MB-231 cells (Fig. 3c) . Moreover, addition of 3 lM MK-2206, an efficient AKT allosteric inhibitor, to the CD73 overexpressed MCF-7 cell medium for 48 hr significantly suppressed phosphorylation of AKT and GSK-3b, as well as expression of b-catenin (Fig. 3d) .
The role of adenosine in CD73-activated AKT/GSK-3b/bcatenin signal pathway
As shown in Figures 4a and 4b , adenosine produced the similar effects on the expression of phosphorylated AKT, phosphorylated GSK-3b and b-catenin as CD73 overexpression, but to a lesser degree. APCP, a CD73 enzyme activity inhibitor, reversed the effects of adenosine (completely) and CD73 overexpression (partially). Similarly, APCP had a weak effect on the activation of AKT/GSK-3b/b-catenin signal pathway after CD73 suppression in MDA-MB-231 cells. Again, adenosine reversed effects of APCP (completely) and CD73 suppression (partially). When incubated with A2AR antagonist SCH 58261, the effect of adenosine on AKT/GSK-3b/b-catenin signal pathway was decreased in CD73 suppressed MDA- MB-231 cells. Otherwise, the addition of selective A2AR agonist NECA reversed the effect of CD73 SiRNA on AKT/ GSK-3b/b-catenin signal pathway in MDA-MB-231 cells (Fig. 4c) .
CD73 promoted the tumorigenicity of breast cancer cells in vivo
About 2 3 10 6 MB-MDA-231 cells infected with CD73 siRNA or control lentivirus were injected subcutaneously into each athymic nude mice. Tumor growth was obviously slower in CD73 suppressed mice than control mice 20 days after injection (Fig. 5b) . Tumor weight was also lower in CD73 suppressed group than control group (Figs. 5a and 5c ). The result suggested that CD73 promoted the tumorigenicity breast cancer cells in vivo.
DISCUSSION
CD73, a glycosylphosphatidylinositol (GPI) anchored cell surface protein, is known as ecto-5 0 -nucleotidase (ecto-5 0 -NT, EC 3.1.3.5). CD73 has both enzymatic and non-enzymatic functions, 19 playing a crucial role in adenosinergic signaling by catalyzing AMP into adenosine and phosphate, which is very important for cell survival, proliferation and motility. 20, 21 Notably, in mutated cells, these events involve in malignant transformation and are considered as a source of tumorigenesis, progression and metastasis. Moreover, adenosine is one of the most important immunosuppressive regulatory molecules in the tumor microenvironment. 6, 22 CD73 was also considered as an immune regulatory molecule and a novel checkpoint inhibitor targets recently. [23] [24] [25] Besides its enzymatic function, CD73 also mediates cancer invasion and metastasis by interaction with extracellular matrix components, such as laminin and fibronectin. 2, 7 Thus, CD73 is a key regulatory molecule in cancer development.
CD73 is overexpressed in a variety of cancer cell lines and cancer patients' biopsies. [26] [27] [28] [29] In our studies, CD73 expression was significantly higher in breast cancer tissues and positively correlated with malignancy of cells and tumor grades. These results are consistent with our previous finding in breast cancer tissue microarray.
18 CD73 also indicates a poor prognosis in triple negative breast cancer. 30 However, using CD73 expression as a prognostic indicator is controversial. For example, a retrospective study suggested that elevated CD73 expression could predict a good prognosis in Stages I-III breast cancer patients. 31 Clearly, further studies are needed. Numerous studies have reported that CD73 overexpression is associated with tumor growth in breast, ovarian, colon and gallbladder cancers, and in melanoma and lymphoma. [26] [27] [28] [29] Consistently, we showed that CD73 promoted breast cancer cell growth both in vitro (colony formation and CCK-8 assays) and in vivo (tumorigenicity assay in murine xenograft model). In addition, our flow cytometry results demonstrated that CD73 could also promote cells from the G0/G1 phase to the S phase, which increases the PIa. Moreover, we found that CD73 could increase the expression of cyclinD1, an important cell cycle protein. Wnt/b-catenin/cyclinD1 is an important signal pathway for embryo growth and development, stem cell self-renewal, tissue structure maintenance and tumor progression. 11, 32 When its cytoplasmic concentration reaches a certain level, b-catenin transfers into the nucleus and accelerates cyclinD1 expression. We showed that CD73 promoted b-catenin expression in both the cytoplasm and nucleus, suggesting that CD73-increased cyclinD1 expression may be mediated by activated b-catenin. Numerous studies showed that an unusually high expression of b-catenin in breast cancer was related to its upstream factors, 33 which was different from bcatenin abnormalities caused by gene mutations in colon, liver and ovarian cancers. GSK-3b is a crucial molecule for degradation of b-catenin in the Wnt/b-catenin pathway, mediating b-catenin phosphorylation. The phosphorylated b-catenin is then identified and degraded by ubiquitin-proteasome. PI3K/Akt pathway is another important pathway, which is often abnormal in a variety of cancers, such as breast, colorectal, ovarian and pancreatic cancers and in endometrial carcinoma. 12, 15 Phosphorylated AKT, the activated form of AKT, inhibits GSK-3b activation through phosphorylation. Thus, two signaling pathways, Wnt/b-catenin and PI3K/Akt, are linked by GSK3b. In this study, for the first time, we found that CD73 could activate the Akt/GSK-3b/b-catenin/cyclinD1 pathway in breast cancer cells, which leads to cell growth. This finding is supported by many studies in normal and cancer cells, including vascular, dental pulp stem cell, glioma and prostate cancer cells. 14, 16, 17 APCP, an enzymatic inhibitor of CD73, could partly reverse the effect of CD73 on the Akt/GSK-3b/b-catenin/ cyclinD1 pathway, which suggests that adenosine played a role. This finding is in consistent with many other reports. 17, 34 However, there were conflicting reports that adenosine could inhibit cell growth and induce apoptosis. Furthermore, our results also demonstrated a nonenzymatic function of CD73, because APCP only partly reversed CD73 effects. In addition, in MDA-MB-231 cells treated with A2AR antagonist SCH 58261 and A2AR agonist NECA, respectively, our data suggested that the effect of adenosine on AKT/GSK-3b/b-catenin signal pathway was partly mediated by adenosine 2A receptor. The adenosine A2A receptor blockade diminished Wnt/b-Catenin signaling was also reported in other studies. 35 Our previous studies of CD73 in breast cancer implicated involvement of membrane molecules, 18 such as estrogen receptor, epidermal growth factors and Phospholipase C. These molecules are closely related to the Akt/GSK-3b/bcatenin/cyclinD1 pathway. Therefore, further studies of the interactions between CD73 and these molecules are needed to define the mechanisms of CD73 on the Akt/GSK-3b/bcatenin/cyclinD1 pathway.
Conclusion
We found that CD73 promoted the growth of human breast cancer cells through the AKT/GSK-3b/b-catenin/cyclinD1 signaling pathway. Thus, CD73 may potentially be an important clinical and prognostic biomarker for breast cancer.
